compass_positive_tagline-01.png
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 03, 2021 07:00 ET | COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
December 01, 2021 07:00 ET | COMPASS Pathways
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...
compass_positive_tagline-01.png
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences
November 30, 2021 08:00 ET | COMPASS Pathways
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
COMPASS Pathways granted fifth US patent for crystalline psilocybin
November 23, 2021 07:00 ET | COMPASS Pathways
London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021
November 09, 2021 07:18 ET | COMPASS Pathways
Highlights: Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25mg dose of...
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 09, 2021 07:00 ET | COMPASS Pathways
Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological...
compass_positive_tagline-01.png
COMPASS Pathways plc to announce third quarter 2021 financial results on 9 November 2021
November 08, 2021 07:00 ET | COMPASS Pathways
London, U.K., Nov. 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
November 03, 2021 08:00 ET | COMPASS Pathways
London, UK – 3 November 2021             COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
October 20, 2021 09:00 ET | COMPASS Pathways
Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health...
compass_positive_tagline-01.png
COMPASS Pathways is granted new US patent for crystalline psilocybin
October 19, 2021 07:00 ET | COMPASS Pathways
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...